HIV

January 2014 Update Research Toward a Cure At the close of 2013 there was another update from Timothy Henrich about the Boston area stem cell transplant cases, revealing that the respite from HIV replication was relatively short-lived. Henrich reported in…

June 2013 By Polly Clayden Last year’s Pipeline Report saw the addition of a new chapter exploring research into antiretroviral treatment optimization. This strategy includes the optimization of approved compounds, and possible future opportunities with those in late-stage development. This…

June 2013 By Polly Clayden The last Pipeline Report described a bumper year for pediatric antiretroviral approvals. This one reports after a year in which new approvals were fewer and far between. Although the pipeline for children continues to look…

June 2013 By Simon Collins and Tim Horn NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction The model of pricing newly approved antiretrovirals (ARVs) higher than current drugs is…

July 2014 By Polly Clayden Since last year’s Pipeline Report, dolutegravir (DTG) was approved for children aged 12 years and older in the United States and Europe.1,2 The approvals for this age group were granted at the same time as…

July 2014 By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz (EFV) is non-inferior to the currently approved one—…

Update July 18, 2014 Disappointing news regarding the "Mississippi baby" case described in this chapter was announced on July 10th by the National Institute of Allergy and Infectious Diseases (NIAID). Viral load rebounded to detectable levels, dashing hopes that a…

July 2014 By Tim Horn and Richard Jefferys The U.S. Food and Drug Administration (FDA) approval of co-formulated tenofovir DF and emtricitabine (Truvada) as preexposure prophylaxis (PrEP) has transformed the HIV prevention landscape, though perhaps more in theory than reality…

July 2014 By Tim Horn and Simon Collins Introduction By 2024, antiretroviral treatment (ART) could be as different from that used today as triple therapy in 1997 was from AZT monotherapy in 1987, or as dramatically evolved as the once-daily…